natgillin/translations-raw huggingface dataset:
The invention also provides the use of microaggregates of the invention in the manufacture of a medicament for treating a patient. 
Izum također daje uporabu mikroagregata iz izuma u proizvodnji medikamenta za liječenje pacijenta.
a platform mounted on said at least one hull, 
- barem jedan trup (5;5),
The method of embodiment 4 wherein the pH is about 1 to about 4 pH units below the pI of the polypeptide. 
Postupak prema patentnom zahtjevu 4, naznačen time, da je pH otprilike 1 do otprilike 4 pH jedinice ispod pl protutijela.
The method according to claim 1, wherein said method comprises an extraction step which comprises the hydrolysis of a cellulose source with an acid. 
Postupak prema bilo kojem zahtjevu od 1 do 3, naznačen time da navedeni postupak sadrži korak ekstrakcije koji se sastoji od hidrolize izvora celuloze sa kiselinom kao što je sumporna kiselina.
adding the obtained solution of gadobenate dimeglumine to an antisolvent B, to obtain a solid form of the gadobenate dimeglumine; and 
dodavanje nastale otopine gadobenat dimeglumina u protuotapalo B, čime se dobiva kruti oblik gadobenat dimeglumina; i
or salt thereof, with a halogenating agent, to form a compound of Formula VI: 
P/ sa sredstvom za halogeniranje, da se dobije spoj s formulom VI ili njegova sol;
one or more metal oxides selected from the group consisting of Cr2O3, chrome ore, Al2O3, spinels, SiO2, silicates, TiO2, ZrO2, oxides of rear earth metals, oxides of iron group metals, and oxides of other transition metals; and/or 
- jedan ili više metalnih oksida odabranih iz skupine koja se sastoji od Cr,O03, rude kroma, AbO3, spinela, SiO., silikata, TiO2, ZrO>, oksida stražnjih zemno metala, oksida od metala skupine željeza i oksida ostalih tranzicijskih metala;
Wind system (1) according to claim 7, characterised in that said permanent magnets are neodymium iron boron magnets. 
Vjetreni sustav (1) prema zahtjevu 4, naznačen time da spomenuti sustavi koji pokreću spomenute budu piezoelektričnog tipa.
The method or the mixture according to claim 4, wherein the antibodies are selected from the group consisting of IgG, such as IgG1, IgG2, IgG3, IgA, such as IgA1, IgA2, IgE, IgD and IgM, such as IgM1, IgM2. 
Postupak prema zahtjevu 1, naznačen time što je antitijelo odabrano iz skupine koja se sastoji od IgG, IgA, IgE, IgD i IgM.
Device as in claim 9, characterised in that the diverting ribs (34) favourably extend to the height of the horizontal diverting rib (31), and with their slanting diverting surface they come out onto the internal surface of the wall of the housing (1). 
HR P20110681 T1 Naprava u skladu s patentnim zahtjevom 9, naznačena time što so izbočine za skretanje (34) po mogućnosti pružaju do visine vodoravne izbočine za skretanje (31), a svojom nagnutom površinom za skretanje izlaze na unutarnju površinu stijenke kućišta (1).
The down-titration would not normally be initiated during a pregnancy, since there is risk of relapse to active addiction, which would pose a danger to the unborn child. 
Smanjivanje doze se uobičajeno neće započinjati za vrijeme trudnoće, pošto postoji rizik recidiva u aktivnu ovisnost, što bi predstavljalo opasnost za nerođeno dijete.
When P resides on oxygen, then k is single bond and 1 is double bond; alternatively, when P resides on nitrogen, then k is double bond and I is single bond. 
Kada P pripada kisiku, tada je k jednostruka veza i 1 je dvostruka veza; alternativno, kada P pripada dušiku tada je k dvostruka veza i 1 je jednostruka veza.
The aqueous phase was neutralized with NaOH (2M), the organics were separated, dried over MgSO4, filtered and evaporated. 
Vodena faza se neutralizira s NaOH (2M), organske faze se odvoje, osuše preko MgSO,, filtriraju i upare.
A microfluidic device according to claim 4, said means for venting consisting of a venting port (7) functioning as a stop flow valve. 
Mikrofluidički uređaj u skladu s patentnim zahtjevom 4, naznačen time što navedeni dio za odzračivanje se sastoji od otvora za odzračivanje (7), koji djeluje kao kao ventil za zatvaranje protoka.
Another preferred embodiment is characterized by the fact that the positioned retaining means of the first coupling elements relative to the helmet shell is provided in the form of a connecting arrangement extending through at least one recess, in particular a screw connection. 
Zaštitna kaciga (2) prema zahtjevu 6, naznačena time da je postavljeni držač prvih spojih elemenata (7) u odnosu na školjku kacige (4) formiran u obliku priključnog spoja, naročito vijčanog spoja koji prolazi kroz barem jedno udubljenje (16).
The aqueous pharmaceutical suspension according to claim 3, wherein the edetate disodium is, by weight/volume (g/100 mL), 0.12% to 0.18%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što dinatrijev edetat iznosi, težinski/volumno (£/190 ml), otprilike 0,12 % do otprilike 0,18 %.
The pharmaceutical composition according to any preceding claim, wherein the crystalline form has an X-ray powder diffraction (XRPD) pattern the same as shown in Figure 2. 
Kristalni oblik prema bilo kojem od zahtjeva 1-3, naznačen time da navedeni kristalni oblik ima spektar difrakcije X-zraka praha (XRPD) isti kao što je prikazan na Slici 2.
The air inversion and steam cure apparatus of claim 1, wherein the container (11) is formed with a top having the slot opening formed by two facing edges (23a, 24a) and at least one edge is moveable towards the other to adjust the size of the gap and press against a liner passing through the slot opening. 
Uređaj za sanaciju zračnom inverzijom i parom prema patentnom zahtjevu 1, naznačen time da je spremnik (11) oblikovan sa vrhom koji ima otvor oblikovan sa dva nasuprotna ruba (23a, 244), te je najmanje jedan rub pokretan u odnosu prema drugom radi podešavanja veličine raspora i pritiska na materijal za sanaciju koji prolazi kroz otvor za umetanje.
and R5 together can optionally form a bivalent radical selected from methylenedioxy or ethylenedioxy; 
R*i R? zajedno mogu po izboru tvoriti bivalentni radikal odabran od metilendioksi ili etilendioksi;
The pharmaceutical composition according to claim 18, further comprising a second antibody or an antigen-binding fragment specific for a second epitope. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 18, naznačen time što dodatno sadrži drugo protutijelo ili antigenski vežući fragment specifičan za drugi epitop.
The upper 213 adheres to said inshoe 227 and its lower edge 228 is folded and glued in contact below the inshoe 227. 
Gornjište 213 prijanja na navedenu unutarnju cipelu 227, a njegov donji dio 228 je preklopljen 1 zalijepljen ispod unutarnje cipele 227.
detecting or determining the activity or amount of the tag attached to the second member of the binding pair, wherein the binding pair is selected from the group of consisting of: 
detektiranja ili određivanja aktivnosti ili količine biljega vezanog s drugim članom vežućeg para, gdje se vežući par bira iz skupine koju čine:
In another presently preferred construction and arrangement, the neck ring arms may be driven between open and closed positions through a plurality of gears. 
U još jednom trenutno preferiranom konstrukcijskom rješenju i izvedbi, hvataljke izdanka kalupa mogu biti otvarane i zatvarane pomoću više zupčanika.
The potentiating effect of eperisone has been even more expressed (see Table 4.). 
Pojačavajući učinak eperisona bio je još jače izražen (vidi tablicu 4.).
wherein the VL domain is humanised, and the sequence of the target binding member comprises amino acids 21-127 of SEQ ID NO:25. 
VL-domena je humanizirana, a sekvenca od ciljanog veznog elementa sadrži aminokiseline 21-127 od SEQ ID NO:25.
The beverage production device according to claim 5, wherein means (18) are provided for evacuating the further steam-producing thermoblock (10) by selectively connecting it with an evacuation outlet (21). 
Naprava za proizvodnju napitaka prema patentnom zahtjevu 5, kod koje je ugrađen mehanizam (18) za pražnjenje dodatnog termobloka za dobivanje vodene pare (10), koji ga selektivno povezuje s izlazom za pražnjenje (21).
The process according to claim 1, wherein the salt of compound of Formula (IV) is an inorganic or organic salt, or combination thereof, such as halide, phosphate, phosphite, carbonate, bicarbonate, sulphate, bisulfate, hydroxide, nitrate, persulfate, sulfite, sulphide, acetate, ascorbate, benzoate, citrate, dihydrogen citrate, hydrogen citrate, oxalate, succinate, tartrate, taurocholate, glycocholate, colate. 
Postupak prema zahtjevu 1, naznačen time da je sol spoja prema formuli (IV) anorganska ili organska sol, odabrana iz skupine koja se sastoji od halida, fosfata, fosfita, karbonata, bikarbonata, sulfata, bisulfata, hidroksida, nitrata, persulfata, sulfita, sulfida, acetata, askorbata, benzoata, citrata, dihidrogen citrata, hidrogen citrata, oksalata, sukcinata, tartrata, taurokolata, glikokolata i kolata.
For example, they may be used to treat glycogen phosphorylase-mediated conditions and diseases. 
Na primjer, mogu se rabiti za liječenje stanja i bolesti kojima upravlja glikogen-fosforilaza.
contacting the water containing sodium nitrite with an activated carbon; 
(c) kontakta vode koja sadrži natrijev nitrit s aktivnim ugljenom;
A pharmaceutical composition for use in the method of any one of the preceding claims, wherein each dose of the pharmaceutical composition administered in the method comprises about 300 mg of the anti-IL-4R antibody or antigen-binding fragment thereof. 
smanjenje rezultata ljestvice 5-D pruritus za najmanje 25 % ili najmanje 30 % u odnosu na osnovicu do 85. dana nakon primjene prve doze farmaceutskog pripravka koji sadrži antitijelo protiv humanog IL-4R ili njegov fragment koji se vezuje za antigen.
Compounds In one aspect of the present invention, provided are compounds of Formula (Ic): or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled derivative thereof, wherein: 
ili njegova farmaceutski prihvatljiva sol, solvat, hidrat, tautomer, stereoizomer ili izotopno označen derivat, pri čemu je: prsten A" izabran od svaki od R', R* 1 R'" neovisno je izabran od vodika i metila;
19–20 shows an open packaging, where the outer part 62 is clicked on to the inner part 60 . 
Slike 19-20 prikazuju otvoreno pakiranje, gdje je vanjski dio 62 skočno pričvršćen na unutarnji dio 60.
oligosaccharide that is preferably prebiotic such as oligofructose and/or resistant maltodextrin; 
- - oligosaharid koji sadržava oligofruktozu i/ili rezistentni maltodekstrin;
The method of claim 88, wherein said supplemental therapy is a weight loss surgery, gastric bypass, gastrectomy, gastric banding, gastric balloon, or gastric sleeve. The method of claim 88, wherein said supplemental therapy is a glucose lowering agent, insulin, GLP1 analogue, biguanide, sulphonylurea, thiazolidinedione, a DPP-4 inhibitor, a bromocriptine formulation, a bile acid sequestrant, metformin, a TZD, a SGLT-2 inhibitor, or any combination thereof. 
Himerni peptid za uporabu sukladno patentnom zahtjevu 25 ili 26, naznačen time što dopunska terapija sadrži: (a) operacija gubitka težine, gastrični bypass, gastrektonomija, želučani balon ili želučani rukav; ili (b) sredstvo za snižavanje glukoze, inzulin, GLP1 analog, bigvanid, sulfonilurea, tiazolidindioni, inhibitor dipeptidil _ peptidaze-4 (DPP-4), formulacija bromokriptina, sekvestrant žučne kiseline, "metformin, tiazolidindioni (TZT), SGLT-2 inhibitor, ili bilo koja njihova kombinacija.
Each floor comprises floor elements 18 which are interconnected and are formed from similar material as the wall elements 2, i.e. from lightweight, insulating and fire retarding material. 
Svaki se pod sastoji od međusobno povezanih podnih elemenata 18, koji su izrađeni od jednakih materijala kao i zidni elementi 2, što znači od laganog, izolirajućeg materijala koji ima svojstvo usporavanja gorenja.
A pyrazolone compound of formula I or a salt thereof: 
Pirazolonski spoj formule 1 ili njegova sol:
A construct comprising a nucleotide sequence set forth in SEQ ID NO:2. The construct of claim 2, wherein said nucleotide sequence is operatively linked to a promoter which functions in plants and said promoter expresses a polypeptide sequence set forth in SEQ ID NO:15. 
Konstrukt koji sadrži (i) nukleotidnu sekvencu prikazanu u SEQ ID NO: 1 i (ii) promotora koji djeluje u biljkama, naznačen time da je nukleotidna sekvenca funkcionalno povezana na promotor tako da ovaj eksprimira polipeptidnu sekvencu prikazanu u SEQ ID NO: 14.
3.5% by weight, of a combustion agent selected from sodium tricitrate, potassium tricitrate and mixture of both, and having a initial air permeability of between 10 CU and 150 CU. 
tež.% sredstva za sagorjevanje odabranog od trinatrij citrata, trikalij citrata i smjesa ova dva spoja, i ima početnu zrakopropusnost između 10 CU i 150 CU.
*R1 is H unless otherwise noted 
*R' je H ako nije drugačije navedeno
The process of claim 1, wherein said first base is selected from the group consisting of triethylamine, 1,5-diazabicyclo[4,3,0]non-5-ene, 1,4-diazabicyclo[2,2,2]octane, and 1,8-diazabicyclo[5,4,0]undec-7-ene, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedenu prvu bazu se bira iz skupine koju čine trietilamin, 1,5-diazabiciklo[4.3.0]non-5-en, 1,4-diazabiciklo[2.2.2]oktan i 1,8-diazabiciklo[5.4.Q0]undec-7-en, te smjese 2 ili više njih.
ii) the amount of RNA contaminant molecules in said purified in vitro- synthesized mRNA is less than 0.01% of the total RNA. 
Metoda prema zahtjevu 1, naznačena time da se manje od 0,01% ukupne RNK u spomenutoj pročišćenoj in vitro sintetiziranoj mRNK sastoji od dvolančanih kontaminantnih RNK molekula.
Like features of the embodiment of FIG. 
Datum podnošenja europske prijave patenta:
The air temperature should drop to 30° C. before continuing. 
Temperatura zraka bi trebalo da padne do 30*C prije nastavka.
Thus viewed from one aspect the invention provides an orally administrable chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester. 
PATENTNI ZAHTJEVI wanman ao Oralno primjenjiv pripravak za žvakanje u obliku jedinične doze koji sadrži ulje-u-vodi emulziju gdje je vodena faza gelirana 1 gdje uljna faza obuhvaća riblje ulje, pri čemu je težina te jedinične doze 0.25-3g.
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or a salt or an ester thereof, for use in the treatment of a condition selected from the group consisting of macular oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, and dry eyes in a mammal, wherein the combined dosage of eicosapentaenoic acid and docosahexaenoic acid is from 5 mmol to 25 mmol per day, and wherein the molar ratio of eicosapentaenoic acid to docosahexaenoic acid is in the range of from 1:1 to 5:1. 
HR P20151039 T1 PATENTNI ZAHTJEVI Eikozapentaenoična kiselina (EPA) i dokozaheksaenoična kiselina (DHA), ili njihova sol ili ester, za upotrebu u liječenju stanja odabranog iz skupine koja se sastoji od makularnog edema, stanja koja uzrokuju oštećenja fotoreceptora retine i/ili retinalnog pigmenta epitelialnih stanica, 1 suhe oči kod sisavca, naznačen time da je kombinirana doza eikozapentaenoične kiseline i dokozaheksaenoične kiseline od 5 mmol do 25 mmol dnevno, i pri čemu je molarni omjer eikozapentaenoične kiseline prema dokozaheksaenoičnoj kiselini u rasponu od 1: 1do 5:1.
The method of para 13, wherein the disease is allergic disorders selected from asthma, chronic obstructive pulmonary disorder (COPD) or respiratory disorders. 
Spoj za uporabu prema patentnom zahtjevu 6, pri čemu je bolest - alergijski poremećaji izabrani od astme, kroničnog opstruktivnog poremećaja pluća (COPD) ili respiratornih poremećaja.
The pressurized metered dose inhaler as claimed in claim 5, wherein the dose of formoterol fumarate dihydrate is 6 or 12 microg. 
Inhalator sa stlačenim inhalatom kako je prijavljen u patentnom zahtjevu 5, naznačen time da je doza formoterol-fumarata 6 ili 12 mg.
2 a is a plan view of the lower part 2 . 
Slika 2a prikazuje nacrt dolnjeg dijela 2.
represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted by a C1-4 alkyl group, a C1-4 alkoxy group or a halogen atom; R2 represents a benzene ring or a naphthalene ring; the rings being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a methylendioxy group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, a C1-4 alkoxy group, a nitro, a cyano, an amino, a C1-5monoalkylamino group or a C2-10 dialkylamino group; 
R1 znači 2-, 3- ili 4-piridinski prsten ili 2-, 4- ili 5-pirimidinski prsten, gdje su ti prsteni izborno supstituirani s C,u alkilnom skupinom, C;.4 alkoksi skupinom ili atomom halogena; R2 predstavlja benzenski prsten ili naftalenski prsten, gdje su ti prsteni izborno supstituirani s 1 do 4 supstitucnta, koje sc bira između Cis alkilnc skupine, metilendioksi skupine, atoma halogena, perhalogenirane Ci.» alkilne skupine, halogenirane C;3 alkilne skupine, hidroksilne skupine, Ca alkoksi skupine, nitro, cijano, amino, C;.s monoalkilamino skupine ili C210 dialkilamino skupine;
A pharmaceutical composition comprising a therapeutically effective amount of the monoclonal antibody of claim 1 or 2 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time da sadrži terapeutski učinkovitu količinu monoklonskog protutijela 12 zahtjeva 1 ili 2 farmaceutski prihvatljiv nosač.
Aqueous 20% sodium hydroxide solution (62.5 ml) was added to a solution of Mosher's ester peak 2 (2.78 g, 5.19 mmol) in methanol (185 ml) and the mixture stirred and heated to reflux for 150 minutes. 
Vodena 20%-tna otopina natrij hidroksida (62.5 ml) se doda u otopinu peak-a 2Mosher-ovog estea (2.78 g, 5.19 mmol) u metanolu (185 ml) i smjesa se miješa 1 zagrijava do refluksa tijekom 150 minuta.
The process of claim 5, wherein the di-saccharide is sucrose. 
Proces iz patentnog zahtjeva 4, gdje disaharid je saharoza.
A pharmaceutical composition according to any previous claim, which is in the form of pellets contained within a capsule, or in the form of pellets that are compressed into a tablet. 
Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je u obliku peleta koji se nalaze u kapsuli, ili u obliku peleta komprimiranih u tabletu.
obtaining by a program an indication of a warning track facility installed (700) within the computing environment, the warning track facility to provide to the program a warning track grace period to perform a function; 
pribavljanje potvrde o instaliranju opreme zone upozorenja (700) unutar računalnog okoliša, oprema zone upozorenja omogućava programu dodatni period zone upozorenja za obavljanje funkcije;
The term "cis-isomeric" refers to the relative orientation of the NR1R2 and Z moieties on the cyclohexene ring (i.e. 
Termin "cis-izomerni" odnosi se na relativnu orijentaciju NR,R, i Z vrsta na cikloheksanskom prstenu (tj.
An apparatus for production of energy from a renewable source 
UREĐAJ ZA PROIZVODNJU ENERGIJE IZ OBNOVLJIVOG IZVORA HR P20170316 T1
The combined fireworks with launching pit and multi-channel fireproof structures of claim 8, characterized in that the bottom surface of the lead channel is aligned with the bottom surface of the first and second wiring groove, and the lead channel is integrated with the first and second wiring groove. 
Kombinirani vatromet s lansirnim oknima i višekanalnim vatrootpornim strukturama u skladu s patentnim zahtjevom 8, naznačen time što je površina dna kanala za vod (24) poravnana s površinom dna prvog i drugog utora za ožičenje (19, 20), a kanal za vod je integriran s prvim i drugim utorom za ožičenje.
A composition as claimed in Claim 1, wherein the cancer is a member of the group consisting of leukemia, breast cancer, ovarian cancer, lung cancer, bladder cancer, prostate cancer, pancreatic cancer, and cervical cancer. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što rak je iz skupine koju čine leukemija, rak dojke, Tak jajnika, rak pluća, rak mokraćnog mjehura, rak prostate, rak gušterače 1 rak vrata maternice.
Metronidazole is a nitroimidazole chemotherapeutic agent having powerful antimicrobial activity and a broad spectrum of action both on Gram+ bacteria and Gram− bacteria. 
Metronidazol je nitroimidazolni kemoterapijski agens koji ima jaku antimikrobnu aktivnost 1 širok spektar djelovanja na Gram+ 1 Gram- bakterije.
in an amount from 31% to 33% by weight and the formulation further comprises: 
(c) u količini od 31% do 33% po masi i formulacija dodatno obuhvaća:
The compound for use of claims 1 to 3, wherein said cancer is non-Hodgkin's lymphoma. 
Tvar za uporabu iz patentnih zahtjeva 1 do 3, pri čemu je naveni tumor non-Hodgkinov limfom.
The vaccine composition of claim 9, wherein the sorbitan fatty acid monoester is a sorbitan monooleate, the ethoxylated fatty acid triester of sorbitan is an ethoxylated trioleate of sorbitan and the non-ionic block-copolymer is a polyoxyethylene/polyoxypropylene polymer (POE-POP). 
11.Sastav cjepiva prema zahtjevu 9, naznačen time, da monocster sorbitanske masne kiseline je sorbitan- monooleat, etoksilirani triester masne kiseline od sorbitana je etoksilirani trioleat od sorbitana i neionski blok-kopolimer je polioksietilen/polioksipropilen-polimer (POE-POP).
The process according to claim 26, wherein the water to be purified contains heavy metal impurities and/or organic impurities. The process according to claim 26 or 27, wherein the water to be purified contains microorganisms. 
Postupak prema zahtjevu 17, pri čemu voda koju treba pročistiti sadrži nečistoće teških metala, organske nečistoće, mikroorganizme, i/ili barem jedan spoj izabran od policikličnih spojeva, kolesterola, i/ili spojeva koji izazivaju endokrine poremećaje.
The pharmaceutical composition for use according to claim 1 or 2, wherein the composition provides steady state plasma levels of 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 50 ng/mL to 250 ng/mL. 
Farmaceutski sastav za upotrebu prema patentnom zahtjevu 1 ili 2, naznačen time da daje stacionarno stanje razine u plazmi 3a-hidroksi-3B-metoksimetil-21-(1’-imidazolil)-5a-pregnan-20-ona u rasponu od 50 ng/ml to 250 ng/ml.
According to the present invention, the first object is solved by providing an anti-cancer vaccine comprising a tumour associated peptide comprising sequence according to SEQ ID No. 1 of the attached sequence listing having an overall length of between 16 and 30 amino acids, wherein said peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-II (HLA class II). 
(n Peptid povezan s tumorom sukladno SEQ ID br. 2 (VMAGDIYSV) ili peptid sukladan SEQ ID br. 2, pri čemu su promijenjeni bočni lanci jedne ili dvije amino kiselina koje su izgubile jednu molekulu vode jer su se vezale za drugu molekulu amino kiseline, te su zbog toga sposobne vezati molekulu ljudskog glavnog histokompatibilnog kompleksa (MHC) klasa I. HLA-A*02.
reacting a compound of formula IV with a compound of formula IVa to provide a compound of formula III: 
(iv) reakciju spoja formule IV sa spojem formule IV, kako bi se dobilo spoj formule III:
The method of claim 8, wherein said nucleic acid sequence is integrated into a virulence gene of said bacterium, wherein the integration of said nucleic acid sequence disrupts expression of the virulence gene or disrupts a coding sequence of the virulence gene. The method of claim 9, wherein the virulence gene is actA or inlB. 
Pripravak prema zahtjevu 9, naznačen time, da je nukleinska kiselma integrirana u gen za viruienciju navedene bakterije 1 integracija navedene nuklemske kiseline narušava ekspresiju gena za virulenciju ili narušava kodirajući slijed za gen za virulenciju, opcionalno gdje je gen za virulenciju actA ili inlB.